AHG Nasdaq Services-Business Services, Nec Financials FY2017βFY2026
Akso Health Group had $13.8M of revenue in fiscal 2026, down 6.4% on the year before. Over five years, revenue changed +51.1% a year on average.
Last close Β· Oct 23, 2026
$1.30
6.6%Hi! I read Akso Health Groupβs latest annual report (fiscal 2026). Here is what stands out:
Good So-so Weak
Are sales growing?
β6.4%
No. Sales fell 6.4% last year.
Does it make a profit?
β135.0%
No. It lost money last year.
Does profit turn into cash?
β92.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
43.3x
One share costs 43.3 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Akso Health Group did it, and the next one. Share prices often move a lot on those days.
Next results
July 22, 2027
Thursday Β· in 269 days
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| Jul 23, 2026 | Period ended Mar 31, 2026 | After the market closes | 20-F β |
| Aug 14, 2025 | Period ended Mar 31, 2025 | After the market closes | 20-F β |
| Jul 30, 2024 | Period ended Mar 31, 2024 | After the market closes | 20-F β |
| Jul 14, 2023 | Period ended Mar 31, 2023 | After the market closes | 20-F β |
| Dec 29, 2022 | Period ended Mar 31, 2022 | After the market closes | 20-F β |
| Jul 28, 2021 | Period ended Mar 31, 2021 | Before the market opens | 20-F β |
| Aug 14, 2020 | Period ended Mar 31, 2020 | After the market closes | 20-F β |
| Jul 31, 2019 | Period ended Mar 31, 2019 | Before the market opens | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Akso Health Group had $13.8M of revenue in fiscal 2026, down 6.4% on the year before. Over five years, revenue changed +51.1% a year on average. Its operating margin was β149.7%, up 975.7Β pts: of every 100 in sales, about β150 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Margins, % of revenue
KIRA Β· Akso Health Group lost $18.7M in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew β28.3% a year.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$12.8M in fiscal 2026, β92.5% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Akso Health Group can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $18.4M | $7.9M | $85.2M | $176M | $0.2M |
| Interest coverage | β4.1x | β | β | β | β |
| Current ratio | 1.2x | 1.8x | 39.5x | 14.2x | 21.8x |
| Quick ratio | 1.1x | 1.6x | 39.5x | 14.2x | 21.7x |
| Total assets | $62.8M | $20.5M | $142M | $215M | $190M |
| Total liabilities | $50.5M | $11.6M | $3.6M | $15.8M | $8.7M |
| Shareholders' equity | $12.3M | $8.7M | $138M | $199M | $181M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Akso Health Group passes 5 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 7 | 1 / 8 | 5 / 8 | 3 / 8 | 3 / 8 | 3 / 8 | 3 / 8 | 3 / 8 | 5 / 8 |
| Accruals ratio | 1.3% | β23.1% | 4.3% | β10.2% | β68.4% | β14.5% | 4.5% | β13.3% | β76.3% | β2.9% |
| Altman Z'' | β | 16.39 | 6.57 | 0.72 | 0.40 | β1.57 | β9.74 | 44.94 | 10.58 | 23.59 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $22.9M | $107M | $3.7M | $6.9M | $1.8M | $6.0M | $13.2M | $2.4M | $14.8M | $13.8M |
| Net interest income | β | $0.6M | β | β | β | β | β | β | β | β |
| Provision for credit losses | β | β | $1.1M | $14.2M | $22.2M | $5.6M | β | β | β | β |
| Gross profit | $22.9M | $107M | β$3.7M | $6.9M | $1.8M | $0.6M | $1.3M | $0.1M | β$0.3M | β$0.0M |
| Research and development | $1.6M | $2.8M | $0.0M | $0.1M | $0.4M | $0.4M | β | β | β | β |
| Operating income | $9.9M | $75.9M | β$7.2M | β$48.1M | β$4.2M | β$3.3M | β$14.3M | β$8.6M | β$166M | β$20.7M |
| Interest expense | β | β | β | β | $2.2M | $0.8M | β | β | β | β |
| Pretax income | $10.1M | $76.5M | β$6.8M | β$46.9M | β$4.3M | β$4.0M | β$13.1M | β$9.1M | β$166M | β$20.7M |
| Income tax | $1.5M | $11.0M | $0.8M | $0.5M | $0.5M | $0.1M | $0.0M | $0.0M | β$30.8M | β$2.0M |
| Net income | $8.6M | $65.5M | $5.5M | β$71.2M | β$34.8M | β$16.9M | β$1.4M | β$9.5M | β$135M | β$18.7M |
| Net income to common | $8.6M | $65.5M | $5.5M | β$71.2M | β | β | β | β$9.5M | β$135M | β$18.7M |
| Diluted EPS | $0.60 | $4.11 | $0.30 | β$4.38 | β$2.13 | β$0.84 | β$0.06 | $0.21 | $0.48 | $0.03 |
| Diluted shares | 0.01B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.05B | 0.29B | 0.72B |
| Cash flow | ||||||||||
| Cash from operations | $8.2M | $87.7M | β$1.7M | β$58.3M | $10.1M | β$8.6M | β$3.3M | $1.4M | $1.2M | β$12.8M |
| Capital expenditure | $0.3M | $0.5M | $0.0M | $0.2M | β | $0.0M | β | β | $0.2M | $0.0M |
| Free cash flow | $7.9M | $87.3M | β$1.7M | β$58.5M | β | β$8.6M | β | β | $1.0M | β$12.8M |
| Depreciation and amortization | $0.1M | $0.2M | $0.0M | $0.1M | $0.0M | $0.0M | β | β | $2.1M | $2.4M |
| Stock-based compensation | $0.0M | $1.8M | $6.6M | $0.3M | $0.1M | $0.4M | β | β | β | β |
| Acquisitions | β | β | β | β | β | β | β | $56.3M | $93.8M | β |
| Share buybacks | β | β | $1.3M | $2.7M | β | β | β | β | β | β |
| Dividends paid | β | β | $19.5M | β | β | β | β | β | β | β |
| Dividends and buybacks | β | β | $20.9M | $2.7M | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $19.2M | $133M | $57.4M | $6.7M | $15.1M | $18.4M | $7.9M | $85.2M | $176M | $0.2M |
| Loans, net | β | $28.7M | $76.4M | $26.7M | $5.5M | β | β | β | β | β |
| Current assets | β | $163M | $97.7M | $52.0M | $30.1M | $62.8M | $20.5M | $142M | $196M | $190M |
| Current liabilities | β | $23.8M | $26.6M | $12.4M | $14.4M | $50.5M | $11.6M | $3.6M | $13.8M | $8.7M |
| Inventory | β | β | β | β | β | $7.8M | $1.7M | $0.2M | $0.2M | $0.2M |
| Property and equipment, net | $0.4M | $0.8M | $1.3M | $0.1M | $0.1M | $0.1M | β | β | $0.0M | $0.0M |
| Goodwill | β | β | β | β | β | β | β | β | $10.8M | β |
| Intangible assets | β | β | β | β | β | β | β | β | $7.9M | $0.1M |
| Total assets | $28.4M | $164M | $173M | $80.5M | $50.7M | $62.8M | $20.5M | $142M | $215M | $190M |
| Total liabilities | $4.9M | $23.8M | $46.8M | $32.4M | $14.4M | $50.5M | $11.6M | $3.6M | $15.8M | $8.7M |
| Shareholders' equity | $23.5M | $140M | $127M | $48.1M | $17.3M | $12.3M | $8.7M | $138M | $199M | $181M |
| Margins | ||||||||||
| Gross margin | 100.0% | 100.0% | β100.2% | 100.0% | 100.0% | 10.1% | 9.6% | 5.1% | β1.9% | β0.1% |
| Operating margin | 43.3% | 70.7% | β194.6% | β695.7% | β241.7% | β54.3% | β108.2% | β357.8% | β1,125.4% | β149.7% |
| EBITDA margin | 43.7% | 70.9% | β194.1% | β694.0% | β240.8% | β54.0% | β | β | β1,110.8% | β132.5% |
| Net margin | 37.4% | 61.1% | 149.7% | β1,029.7% | β1,984.6% | β280.9% | β10.3% | β391.8% | β913.4% | β135.0% |
| FCF margin | 34.5% | 81.4% | β47.1% | β845.7% | β | β143.9% | β | β | 6.9% | β92.5% |
| Net interest share of revenue | β | 0.6% | β | β | β | β | β | β | β | β |
| Returns | ||||||||||
| Return on capital employed | β | 54.2% | β4.9% | β70.6% | β11.7% | β26.5% | β161.4% | β6.2% | β82.7% | β11.4% |
| Return on equity | 36.5% | 80.1% | 4.2% | β81.6% | β106.5% | β114.0% | β12.9% | β12.9% | β80.0% | β9.8% |
| Return on assets | 30.2% | 68.1% | 3.3% | β56.1% | β53.1% | β29.7% | β3.3% | β11.6% | β75.6% | β9.2% |
| Return on tangible equity | 36.5% | 46.8% | 4.4% | β148.0% | β201.6% | β137.2% | β15.6% | β6.8% | β74.8% | β10.3% |
| Growth | ||||||||||
| Revenue growth | β | 368.0% | β96.6% | 87.1% | β74.6% | 241.9% | 119.7% | β81.7% | 512.1% | β6.4% |
| Net income growth | β | 664.0% | β91.6% | β1,386.9% | β | β | β | β | β | β |
| EPS growth | β | 585.0% | β92.7% | β1,560.0% | β | β | β | β | 128.6% | β93.8% |
| FCF growth | β | 1,004.4% | β102.0% | β | β | β | β | β | β | β1,350.9% |
| Share count change | β | 12.6% | 11.0% | β7.9% | 0.2% | 22.1% | 15.1% | 106.3% | 504.4% | 153.5% |
| Financial health | ||||||||||
| Interest coverage | β | β | β | β | β2.0x | β4.1x | β | β | β | β |
| Current ratio | β | 6.8x | 3.7x | 4.2x | 2.1x | 1.2x | 1.8x | 39.5x | 14.2x | 21.8x |
| Quick ratio | β | 6.8x | 3.7x | 4.2x | 2.1x | 1.1x | 1.6x | 39.5x | 14.2x | 21.7x |
| Provision / loans | β | β | 1.4% | 53.3% | 403.8% | β | β | β | β | β |
| Capital allocation | ||||||||||
| Capex / revenue | 1.3% | 0.4% | 0.2% | 2.9% | β | 0.1% | β | β | 1.0% | 0.0% |
| Stock comp / revenue | 0.0% | 1.7% | 178.2% | 5.0% | 3.2% | 6.5% | β | β | β | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 1.0 | 5.0 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 | 5.0 |
| Altman Z'' | β | 16.4 | 6.6 | 0.7 | 0.4 | β1.6 | β9.7 | 44.9 | 10.6 | 23.6 |
| Accruals ratio | 1.3% | β23.1% | 4.3% | β10.2% | β68.4% | β14.5% | 4.5% | β13.3% | β76.3% | β2.9% |
Source: SEC EDGAR XBRL filings (CIK 0001702318). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Per-share figures are per US-listed share (1 ADS = 3 ordinary shares). For information only β not investment advice. Check the original filings before relying on any figure.
